Universal Vision Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 10, 2022
Share
Universal Vision Biotechnology Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 789.28 million compared to TWD 614.77 million a year ago. Net income was TWD 187.05 million compared to TWD 127.5 million a year ago. Basic earnings per share from continuing operations was TWD 2.3429 compared to TWD 1.5905 a year ago. Diluted earnings per share from continuing operations was TWD 2.3429 compared to TWD 1.5905 a year ago.
For the six months, sales was TWD 1,624.88 million compared to TWD 1,225.05 million a year ago. Net income was TWD 400.39 million compared to TWD 276.94 million a year ago. Basic earnings per share from continuing operations was TWD 5.0095 compared to TWD 3.4667 a year ago. Diluted earnings per share from continuing operations was TWD 5 compared to TWD 3.4667 a year ago.
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD is a Taiwan-based company principally engaged in the trading of ophthalmic supplies and the provision of eye treatment and related medical services. The Company provides laser vision correction equipment and services, as well as the trading of medical drugs, optical glasses and contact lenses. In addition, the Company is involved in the leasing of medical places, the planning of clinic operation, as well as the provision of medical cosmetology services. The Company operates its businesses mainly in Taiwan market.
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD. 
